Showing 251-260 of 355 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Transcriptional memory in human islet organogenesis | Lundquist Institute for Biomedical Medical Innovation at Harbor‐UCLA Medical Center (The Lundquist Institute) | Eiji Yoshihara | Cures | 01-April-2022 to 31-March-2027 | $749,995.50 |
| Assessment of NovoSphere™ Hydrogel Encapsulation to Enable High-Loading and Extended Release of Tegoprubart for Subcutaneous Administration | Likarda, Inc | Lisa Stehno-Bittel | Cures | 15-June-2026 to 15-December-2026 | $301,200.00 |
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 15-May-2026 to 31-May-2027 | $200,000.00 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8,913,450.00 |
| Study of ALDH3B2 as a regulator of pancreatic beta cell neogenesis | Joslin Diabetes Center Inc. | Jian Li | Cures | 01-August-2023 to 31-July-2026 | $212,708.89 |
| Validation of a new approach for cardiovascular disease risk stratification and therapeutic targeting in T1D | Joslin Diabetes Center Inc. | Myra Lipes | Improving Lives | 01-September-2023 to 30-June-2027 | $1,341,376.33 |
| Harnessing insulin signaling in β-cells to counter type 1 diabetes | Joslin Diabetes Center Inc. | Namrata Shukla | Cures | 01-March-2024 to 28-February-2027 | $216,326.98 |
| Targeting RNLS for Type 1 Diabetes Therapy | Joslin Diabetes Center Inc. | Peng Yi | Cures | 01-June-2025 to 31-May-2028 | $1,349,997.00 |
| A Novel Bifunctional Biologic for Type 1 Diabetes | Johns Hopkins University | Giorgio Raimondi | Cures | 01-February-2025 to 31-January-2028 | $995,376.00 |
| Exploring Immunologic Mechanisms of Indirect (Encapsulated) Islet Graft Rejection | Johns Hopkins University | Joshua Doloff | Cures | 01-November-2025 to 31-October-2028 | $1,125,000.00 |